Evidence map›Paper›PMID 34733999›Full record

ArticleAnnals of translational medicine2021

T cell exhaustion drives osteosarcoma pathogenesis.

Cheng-Ying Sun, Zhe Zhang, Lei Tao, Fei-Fei Xu, Hui-Yuan Li, Hui-Yu Zhang, Wei Liu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Osteoimmunology in bone malignancies: a symphony with evil.Journal of the National Cancer Center · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Cheng-Ying SunDepartment of Geriatrics, the Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Zhe ZhangDepartment of Geriatrics, the Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Lei TaoDepartment of Geriatrics, the Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Fei-Fei XuDepartment of Geriatrics, the Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Hui-Yuan LiDepartment of Geriatrics, the Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Hui-Yu ZhangDepartment of Geriatrics, the Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Wei LiuDepartment of Geriatrics, the Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Fourth Affiliated Hospital of China Medical University · CNChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteosarcoma (OS) is a rare cancer with a bimodal age distribution that peaks in children and young adults. It has been shown that the expression of programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1) on tumor-infiltrating immune cells negatively correlates with prognosis of OS patients. However, a comprehensive assessment of the tumor-infiltrating immune cells in OS and their function has not been performed.

methodsCD8

resultsMacrophages and CD3

conclusionsThese results highlight that TIM3 blockade might be a viable therapeutic option and should be tested in additional preclinical models.

Indexed as

exhausted T cellsOsteosarcomaT cell immunoglobulin and mucin-domain containing 3 (TIM3)tumor microenvironment (TME)

Identifiers

PMID34733999
PMCPMC8506720
OpenAlexW3202159225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.